The IPO Buzz: Iambic Therapeutics (IAM Proposed) Launches $150 Million IPO
Iambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point of its range, according to its S-1/A filing dated Oct. 8, 2026. At pricin..
Read more October 8, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Retension Pharmaceuticals | RTSN | 3.3 | $ 39.6 mil | 10/9/2026 Friday | S/O | S/O |
| TRex Bio, Inc. | TRXB | 8.3 | $ 125.0 mil | 10/9/2026 Friday | S/O | S/O |
| Bitari | BIAI | 4.3 | $ 30.0 mil | 10/14/2026 Week of | S/O | S/O |
Last 100 IPOs - October 7, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 40 |
| Number Down: | 59 |
| Number Unchanged: | 1 |
| Percentage Change From Issue Price: | 0.04% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 7, 2026
| Number of IPOs priced (Excluding 152 units) : | 125 |
| Number Up: | 47 |
| Number Down: | 77 |
| Number Unchanged: | 1 |
| Total Return From Issue Price: | -0.82% |
| The Nasdaq Composite Index YTD % Change | 35.22% |